Open AccessGastric Metastatic Grade 3 Well-Differentiated Neuroendocrine Tumor: A Case Report
Author(s) -
M.A. Mokhlis,
M. Allaoui,
L. Alaoui,
C.el M’hadi,
M.R. Khmamouch,
T. Mahfoud,
K.Alaoui Slimani,
M. Oukabli,
R. tanz,
M. Ichou
Publication year - 2022
Publication title -
scholars journal of applied medical sciences
Language(s) - English
Resource type - Journals
eISSN - 2347-954X
pISSN - 2320-6691
DOI - 10.36347/sjams.2022.v10i02.012
Subject(s) - neuroendocrine tumors , medicine , pathological , folfox , stomach , neuroendocrine differentiation , pathology , oncology , gastroenterology , cancer , oxaliplatin , colorectal cancer , prostate cancer
Background: Neuroendocrine neoplasms (NENs) are rare tumors .They are defined by the expression of specific biomarkers. Progress in pathological diagnosis has allowed a better identification and classification of these tumors. The 2019-revised World Health Organization (WHO) classification of tumors of endocrine organs classifies grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NENs) into well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinomas (NEC G3). There are few reported cases of NET G3 occurring in the stomach. Case presentation: A 63-year- man who suffers from dysphagia and Melaena. Fibroscopy revealed a ulcero-budding process of the cardia. Pathologic examination concluded on NET well-differentiated grade 3. Surgical exploration showed peritoneal carcinomatosis and histologically confirmed liver metastases. He underwent chemotherapy with modified folfox 4 protocol for 3 months with satisfactory clinico-morphological response. Conclusion: A definite diagnosis of NET G3 or NEC G3 must be made to determine the appropriate treatment strategy for patients with GEP-NEN G3. the efficacy of treatments for G3 NETs appear modest, as evidenced by the short PFS observed, therefore, more effective therapies are needed with Further case reports and case series. Keywords: Neuroendocrine tumor G3, stomach, modified FOLFOX 4.